A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology

BACKGROUND: Nintedanib is a new tyrosine kinase inhibitor and growth factor antagonist. It can be used to treat idiopathic pulmonary fibrosis diseases. Nintedanib has poor solubility in the intestinal tract environment, which leads to low bioavailability of just 4.7%. METHODS: In this study, a ninte...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongfei, Du, Kunyu, Li, Dongli, Du, Yi, Xi, Jumei, Xu, Ying, Shen, Yan, Jiang, Tao, Webster, Thomas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294062/
https://www.ncbi.nlm.nih.gov/pubmed/30587966
http://dx.doi.org/10.2147/IJN.S181002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294062/
https://www.ncbi.nlm.nih.gov/pubmed/30587966
http://dx.doi.org/10.2147/IJN.S181002

Ejemplares similares